Halozyme Therapeutics, Inc. (NASDAQ:HALO) Q4 2022 Earnings Call Transcript
Operator: Good afternoon. My name is Regina, and I will be your conference operator today.
Halozyme Therapeutics Inc. (HALO)
Market is closed
News
- First
- << Previous
- 21 - 30
- Next >>
5 High Growth Pharma Stocks that are Profitable
Halozyme Therapeutics, Inc. (NASDAQ:HALO)'s third quarter of 2022 results saw the firm bring in $209 million in revenue, which marked a strong 80% annual growth.
Is Halozyme Therapeutics (HALO) a Growing Stock to Invest In?
Carillon Tower Advisers, an investment management company, released its “Carillon Eagle Small Cap Growth Fund” fourth quarter 2022 investor letter. A copy of the same can be downloaded here.
Multiple Reasons For the Outperformance of Halozyme Therapeutics (HALO)
Bernzott Capital Advisors, an investment management firm, published its “US Small Cap Value Fund” fourth-quarter 2022 investor letter, a copy of which can be downloaded here.
Is Halozyme Therapeutics (HALO) a High Growth Company?
Artisan Partners, an investment management company, released its “Artisan Mid Cap Fund” fourth quarter 2022 investor letter. A copy of the same can be downloaded here.
11 Best Diabetes Stocks To Buy Now
The global diabetes market is segmented based on the type, drug class, and devices used to treat the condition.
Should You Hold Halozyme Therapeutics (HALO)?
Artisan Partners, an investment management company, released its “Artisan Small Cap Fund” third quarter 2022 investor letter. A copy of the same can be downloaded here.
Should You Consider Investing in Halozyme Therapeutics (HALO)?
Carillon Tower Advisers, an investment management firm, published its “Carillon Eagle Small Cap Growth Fund” second quarter 2022 investor letter – a copy of which can be downloaded here.
Is Halozyme Therapeutics (HALO) A Good Long-Term Investment?
Artisan Partners, an investment management company, released its “Artisan Small Cap Fund” second quarter 2022 investor letter. A copy of the same can be downloaded here.
Is Halozyme Therapeutics (HALO) a Smart Long-Term Buy?
Bernzott Capital Advisors, an investment management firm, published its “US Small Cap Value Fund” first quarter 2022 investor letter – a copy of which can be downloaded here.
- First
- << Previous
- 21 - 30
- Next >>
Billionaire Hedge Funds
